cost-effectiveness research

In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...

In a...

08/14/2017

Journal of Clinical Pathways

Research in Review

Costs and Complications Associated With Repeated Breast-Conserving Surgery for Breast Cancer

08/09/2017

JCP Editors

More than 23% of patients with breast cancer who undergo breast-conserving surgery followed by subsequent surgery do not receive the full benefits of surgery due to added costs and complications, according...

More...

08/09/2017

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Multiple Myeloma Therapies From a Payer‚Äôs Perspective

08/02/2017

JCP Editors

A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma, published in the Journal of Managed Care & Specialty Pharmacy (August...

A...

08/02/2017

Journal of Clinical Pathways

Research in Review

Mastectomy Not Cost-Effective for Most Patients With Ovarian Cancer

07/12/2017

JCP Editors

Risk-reducing mastectomy within five years of ovarian cancer diagnosis is not cost-effective compared with surveillance for patients with BRCA mutations, according to research published in Annals of Surgical Oncology...

...

07/12/2017

Journal of Clinical Pathways

Research in Review

Common Second-Line Treatment for Liver Cancer Deemed Not Cost-Effective

07/03/2017

JCP Editors

A conventional second-line treatment for hepatocellular carcinoma offers only a marginal increase in quality-adjusted life-years (QALYs) at a significantly high cost, according to an analysis published in Cancer...

A...

07/03/2017

Journal of Clinical Pathways